Literature DB >> 19273695

When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab.

Hans-Joachim Schmoll, Dirk Arnold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19273695     DOI： 10.1200/JCO.2008.20.6284

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

Review 1.  EpCAM and its potential role in tumor-initiating cells.

Authors:  Sannia Imrich; Matthias Hachmeister; Olivier Gires
Journal:  Cell Adh Migr       Date:  2012 Jan-Feb       Impact factor: 3.405

2.  A high-content screen for small-molecule regulators of epithelial cell-adhesion molecule (EpCAM) cleavage yields a robust inhibitor.

Authors:  Jana Ylva Tretter; Kenji Schorpp; Elke Luxenburger; Johannes Trambauer; Harald Steiner; Kamyar Hadian; Olivier Gires; Dierk Niessing
Journal:  J Biol Chem       Date:  2018-04-26       Impact factor: 5.157

3.  Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.

Authors:  Daniel A Vallera; Bin Zhang; Michelle K Gleason; Seunguk Oh; Louis M Weiner; Dan S Kaufman; Valarie McCullar; Jeffrey S Miller; Michael R Verneris
Journal:  Cancer Biother Radiopharm       Date:  2013-04-23       Impact factor: 3.099

4.  Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.

Authors:  Ranju Ralhan; Helen C-H He; Anthony K-C So; Satyendra C Tripathi; Manish Kumar; Md Raghibul Hasan; Jatinder Kaur; Lawrence Kashat; Christina MacMillan; Shyam Singh Chauhan; Jeremy L Freeman; Paul G Walfish
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

5.  EpCAM modulates NF-κB signaling and interleukin-8 expression in breast cancer.

Authors:  Narendra V Sankpal; Timothy P Fleming; William E Gillanders
Journal:  Mol Cancer Res       Date:  2013-02-01       Impact factor: 5.852

6.  Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma.

Authors:  A Wang; R Ramjeesingh; C H Chen; D Hurlbut; N Hammad; L M Mulligan; C Nicol; H E Feilotter; S Davey
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

7.  Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.

Authors:  Markus Münz; Alexander Murr; Majk Kvesic; Doris Rau; Susanne Mangold; Stefan Pflanz; John Lumsden; Jörg Volkland; Jan Fagerberg; Gert Riethmüller; Dominik Rüttinger; Peter Kufer; Patrick A Baeuerle; Tobias Raum
Journal:  Cancer Cell Int       Date:  2010-11-02       Impact factor: 5.722

8.  Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.

Authors:  Jasmeet Assi; Gunjan Srivastava; Ajay Matta; Christina MacMillan; Ranju Ralhan; Paul G Walfish
Journal:  PLoS One       Date:  2015-02-19       Impact factor: 3.240

Review 9.  New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

Authors:  Isabel Corraliza-Gorjón; Beatriz Somovilla-Crespo; Silvia Santamaria; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

Review 10.  Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.

Authors:  Salvatore Giovanni Vitale; Antonio Simone Laganà; Stella Capriglione; Roberto Angioli; Valentina Lucia La Rosa; Salvatore Lopez; Gaetano Valenti; Fabrizio Sapia; Giuseppe Sarpietro; Salvatore Butticè; Carmelo Tuscano; Daniele Fanale; Alessandro Tropea; Diego Rossetti
Journal:  Int J Mol Sci       Date:  2017-05-20       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.